On January 12, Eli Lilly announced a collaboration with Nvidia to establish an AI innovation laboratory in the San Francisco Bay area, committing up to $1 billion in joint investment over five years. The facility will bring together Lilly’s drug discovery scientists and Nvidia’s AI engineers to develop specialized machine-learning models aimed at accelerating early-stage compound identification. By leveraging Nvidia’s latest AI processors and Lilly’s extensive clinical-trial data, the partners aim to reduce discovery timelines, which traditionally exceed a decade and can cost over $1 billion per successful molecule. This initiative builds on Lilly’s prior investments in AI, including the construction of an industry-leading supercomputer last year and the launch of TuneLab, a platform that provides smaller biotechs with AI-driven drug-design capabilities.

Shares dipped following reports that the Food and Drug Administration has delayed its decision on Lilly’s investigational oral obesity treatment, orforglipron, pushing the expected ruling to April. Investors are recalibrating expectations after initial optimism that the new pill would secure approval in the first quarter. While the delay prolongs uncertainty, it allows competitors additional time to advance their own programs. Analysts note that, despite the setback, orforglipron remains a key candidate that could address both obesity and diabetes indications and diversify Lilly’s growth runway beyond its injectable weight-loss franchise.

Lilly’s third-quarter results underscore robust fundamentals: global revenue climbed 54% year-over-year to $17.6 billion, and adjusted earnings per share surged by 480% to $6.21, propelled largely by its injectable weight-management drug tirzepatide. As the current best-selling medicine globally, tirzepatide is expected to sustain double-digit top-line expansion through the decade. Beyond obesity, Lilly is advancing orforglipron and pipeline candidates such as retatrutide, both targeting obesity and type 2 diabetes with Phase 3 data readouts anticipated later this year. Additionally, recent approvals in oncology, immunology, and Alzheimer’s disease demonstrate Lilly’s commitment to diversifying its therapeutic portfolio and reducing reliance on any single franchise.

Lilly continues to generate strong free cash flow, enabling consistent dividend increases that have averaged a compound annual growth rate of over 15% across the last five years. The company’s investment-grade balance sheet supports a sustainable payout, while ongoing capital allocation prioritizes high-return R&D projects alongside shareholder distributions. Yield-focused investors benefit from Lilly’s combination of above-average dividend growth and exposure to secular trends in obesity, diabetes, and AI-driven drug discovery.